
1. malar j. 2016 may 27;15(1):295. doi: 10.1186/s12936-016-1344-0.

sustained efficacy artesunate-sulfadoxine-pyrimethamine plasmodium
falciparum yemen renewed call adjunct single dose primaquine to
clear gametocytes.

atroosh wm(1)(2), al-mekhlafi hm(3)(4)(5), snounou g(6), al-jasari a(7), sady
h(1), nasr na(1), lau yl(1), surin j(1)(8).

author information: 
(1)department parasitology, faculty medicine, university malaya, 50603, 
kuala lumpur, malaysia.
(2)department microbiology parasitology, faculty medicine health
sciences, university aden, aden, yemen.
(3)department parasitology, faculty medicine, university malaya, 50603, 
kuala lumpur, malaysia. halmekhlafi@yahoo.com.
(4)endemic tropical diseases unit, medical research center, jazan university,
jazan, kingdom saudi arabia. halmekhlafi@yahoo.com.
(5)department parasitology, faculty medicine health sciences, sana'a
university, sana'a, yemen. halmekhlafi@yahoo.com.
(6)upmc université paris 06, inserm (institut national de la santé et de la
recherche medicale), centre d'immunologie et des maladies infectieuses
(cimi-paris), umr 1135, erl cnrs 8255 (centre national de la recherche
scientifique), sorbonne universités, 91 boulevard de l'hôpital, f-75013, paris,
france. georges.snounou@upmc.fr.
(7)national malaria control programme, ministry public health population, 
sana'a, yemen.
(8)centre research innovation, taylor's university, 47500, subang jaya,
selangor, malaysia.

background: yemen, artesunate plus sulfadoxine-pyrimethamine (as + sp) has
been used first-line treatment uncomplicated falciparum malaria, which
accounts 99 % malaria cases. evidence resistance sp
is increasing, potential negative impact efficacy, particular on
curbing transmission. study aims: (a) evaluate therapeutic efficacy
of as + sp treatment uncomplicated falciparum malaria yemen; (b) to
investigate frequency mutations plasmodium falciparum genes associated 
with resistance (kelch 13 propeller domain, pfk13) sp (dihydrofolate
reductase, pfdhfr, dihydropteroate synthase, pfdhps); (c) assess the
adequacy act clear gametocytes.
methods: 28-day vivo evaluation clinical parasitological response
to three-day course as + sp carried two areas high endemicity
(hodeidah al-mahwit provinces, tehama region) yemen according standard 
who protocol 2009. clinical parasitological indices monitored a
28-day follow-up, outcome pcr-corrected. frequencies mutations
in pfdhfr, pfdhps, pfk13 genes obtained sequencing following
amplification.
results: eighty-six patients completed study, cure rate 96.5 %
(94.2 % pcr-uncorrected). whereas four (4.7 %) patients still showed parasitaemia
on day 2 post-treatment, found negative asexual malaria stages on
days 3 7. efficacy gametocyte clearance poor (14.5, 42.5 and
86.0 % days 7, 14 28, respectively), gametocytes persisting
throughout study patients. isolates sequenced pfk13
propeller domain wild-type allele, mutations associated sp failure 
observed pfdhfr double mutation (s108n + n51i) found 65.4 % 
of isolates sequenced.
conclusion: yemen, as + sp therapy remains effective treatment of
uncomplicated falciparum malaria. mutations detected pfk13 pfdhps,
though double mutations observed pfdhfr. observed persistent
gametocytaemia re-enforces calls add single dose primaquine act in
order minimizes potential transmission enhance regional efforts to
eliminate malaria.

doi: 10.1186/s12936-016-1344-0 
pmcid: pmc4882835
pmid: 27234587  [indexed medline]

